JANAY KISSINGER: Open Payments
NPI 1669525721 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,489 in 148 payments from 25 companies in 2025. Trend: 2023 $2,795 · 2024 $3,760 · 2025 $3,489
Food & beverage: $3,412Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $691 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $411 |
| Madrigal Pharmaceuticals | 11 | $314 |
| Lilly USA, LLC | 12 | $304 |
| Janssen Biotech, Inc. | 9 | $301 |
| QOL Medical, LLC | 7 | $224 |
| Ardelyx, Inc. | 8 | $199 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $174 |
| Gilead Sciences, Inc. | 8 | $159 |
| GENZYME CORPORATION | 5 | $127 |
Products named: ENTYVIO, REZDIFFRA, TREMFYA, RINVOQ, OMVOH, Sucraid, IBSRELA, XIFAXAN.
Industry payments across MO — which companies pay providers there.
